Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Redefining Idiopathic Normal Pressure Hydrocephalus Using AI-Driven Brain Volumetry

  • Al-Nusaif, Murad
  • Duch Vega, Paula
  • Sahuquillo, Juan
  • Sahuquillo-Muxi, Aasma
  • Poca, Maria A.
MRI volumetry; Artificial intelligence; Brain atrophy, Volumetria de ressonància magnètica; Intel·ligència artificial; Atròfia cerebral, Volumetría por resonancia magnética; Inteligencia artificial; Atrofia cerebral, Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible cause of gait disturbance and cognitive impairment in older adults, yet its diagnosis remains challenging and controversial. The core difficulty lies in distinguishing true hydrocephalus from ventricular enlargement secondary to cerebral atrophy or neurodegenerative disease, a distinction now recognized as non-binary. In many patients, ventricular enlargement reflects a continuum ranging from predominantly hydrocephalic iNPH to mixed pathological states combining impaired cerebrospinal fluid (CSF) dynamics and neurodegeneration. Conventional neuroradiological markers, including the Evans Index, the callosal angle, and the disproportionately enlarged subarachnoid-space hydrocephalus (DESH) pattern, provide useful qualitative guidance but are limited by their two-dimensional nature, interobserver variability, and poor sensitivity for differential diagnosis and outcome prediction. Over the past decade, advances in artificial intelligence-based brain volumetry (AI-BrV) have introduced a new paradigm for quantitative structural assessment. By enabling automated, anatomically precise, and reproducible three-dimensional quantification of ventricular and extraventricular CSF, cortical and subcortical gray matter, deep gray matter nuclei, and periventricular white matter, AI-BrV addresses many limitations of traditional imaging approaches. Beyond absolute volume measurements, AI-BrV enables the derivation of composite indices and ratios that may capture disease-specific structural phenotypes and better reflect the underlying pathophysiology of ventricular enlargement. Importantly, AI-BrV pipelines can be applied retrospectively to large legacy neuroimaging datasets and compared with extensive publicly available repositories, facilitating normative modeling, cross-disease analyses, and external validation of volumetric biomarkers. When integrated with clinical data and multivariable statistical or machine-learning frameworks, these approaches hold promise for improving patient selection, refining disease categorization, and supporting more rational decision-making regarding CSF diversion. In this context, AI-BrV offers a unifying framework for reconciling divergent clinical perspectives and advancing iNPH toward a more precise, reproducible, and evidence-based diagnostic and therapeutic paradigm., This study was partially funded by the Instituto de Salud Carlos III (ISCIII) through project PI25/01408, co-funded by the European Union and by the grant 2021SGR/00810 from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Departament de Recerca i Universitats de la Generalitat de Catalunya, Spain. This project also received support from the European Union’s Horizon Europe research and innovation programme under the Marie Sklodowska-Curie Grant Agreement No. 101081441, Agencia Estatal de Investigación (AEI) (SCOSWEAR PID2023-147553OB-I00, SAFEICP PLEC2022-009290), Fundació CELLEX Barcelona, Fundació Mir-Puig, Generalitat de Catalunya (CERCA, AGAUR, RIS3CAT, SGR-01457), European Commission (VASCOVID, TINYBRAINS, fastMOT, Prometeus), LitMuscleDTS22/00023 from Institute de Salud Carlos III and NIH R01NS090874.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Redefining Idiopathic Normal Pressure Hydrocephalus Using AI-Driven Brain Volumetry

  • Al-Nusaif, Murad
  • Duch Vega, Paula
  • Sahuquillo, Juan
  • Sahuquillo-Muxi, Aasma
  • Poca, Maria A.
MRI volumetry; Artificial intelligence; Brain atrophy, Volumetria de ressonància magnètica; Intel·ligència artificial; Atròfia cerebral, Volumetría por resonancia magnética; Inteligencia artificial; Atrofia cerebral, Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible cause of gait disturbance and cognitive impairment in older adults, yet its diagnosis remains challenging and controversial. The core difficulty lies in distinguishing true hydrocephalus from ventricular enlargement secondary to cerebral atrophy or neurodegenerative disease, a distinction now recognized as non-binary. In many patients, ventricular enlargement reflects a continuum ranging from predominantly hydrocephalic iNPH to mixed pathological states combining impaired cerebrospinal fluid (CSF) dynamics and neurodegeneration. Conventional neuroradiological markers, including the Evans Index, the callosal angle, and the disproportionately enlarged subarachnoid-space hydrocephalus (DESH) pattern, provide useful qualitative guidance but are limited by their two-dimensional nature, interobserver variability, and poor sensitivity for differential diagnosis and outcome prediction. Over the past decade, advances in artificial intelligence-based brain volumetry (AI-BrV) have introduced a new paradigm for quantitative structural assessment. By enabling automated, anatomically precise, and reproducible three-dimensional quantification of ventricular and extraventricular CSF, cortical and subcortical gray matter, deep gray matter nuclei, and periventricular white matter, AI-BrV addresses many limitations of traditional imaging approaches. Beyond absolute volume measurements, AI-BrV enables the derivation of composite indices and ratios that may capture disease-specific structural phenotypes and better reflect the underlying pathophysiology of ventricular enlargement. Importantly, AI-BrV pipelines can be applied retrospectively to large legacy neuroimaging datasets and compared with extensive publicly available repositories, facilitating normative modeling, cross-disease analyses, and external validation of volumetric biomarkers. When integrated with clinical data and multivariable statistical or machine-learning frameworks, these approaches hold promise for improving patient selection, refining disease categorization, and supporting more rational decision-making regarding CSF diversion. In this context, AI-BrV offers a unifying framework for reconciling divergent clinical perspectives and advancing iNPH toward a more precise, reproducible, and evidence-based diagnostic and therapeutic paradigm., This study was partially funded by the Instituto de Salud Carlos III (ISCIII) through project PI25/01408, co-funded by the European Union and by the grant 2021SGR/00810 from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Departament de Recerca i Universitats de la Generalitat de Catalunya, Spain. This project also received support from the European Union’s Horizon Europe research and innovation programme under the Marie Sklodowska-Curie Grant Agreement No. 101081441, Agencia Estatal de Investigación (AEI) (SCOSWEAR PID2023-147553OB-I00, SAFEICP PLEC2022-009290), Fundació CELLEX Barcelona, Fundació Mir-Puig, Generalitat de Catalunya (CERCA, AGAUR, RIS3CAT, SGR-01457), European Commission (VASCOVID, TINYBRAINS, fastMOT, Prometeus), LitMuscleDTS22/00023 from Institute de Salud Carlos III and NIH R01NS090874.